Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins. Design of rational studies for the use of selinexor in combination with other therapeutic agents, such as immu...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Frontiers Media S.A.
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/3bc2ec99a6694182a242490b99350987 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|